| Andrew James Mullin, PHARMD | |
|
1375 E Boot Rd, West Chester, PA 19380-5934 | |
| (610) 241-1061 | |
| Not Available |
| Full Name | Andrew James Mullin |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1375 E Boot Rd, West Chester, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154922169 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RP453590 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Andrew James Mullin, PHARMD 1375 E Boot Rd, West Chester, PA 19380-5934 Ph: (610) 241-1061 | Andrew James Mullin, PHARMD 1375 E Boot Rd, West Chester, PA 19380-5934 Ph: (610) 241-1061 |
News Archive
"Real-Time Care Experience Feedback Using QR Codes," a Penn State project that allows hospital patients to inform hospital personnel of their experiences - good or bad - in real time, is the winner of the 2012 REACH Developer Challenge, sponsored by AcademyHealth and part of the Health 2.0 Developer Challenge.
USA Today: "The shortage of primary care doctors could lead to longer waits not only for primary care, but also for specialty care as well as greater use of expensive emergency rooms for non-emergencies, researcher Walt Zywiak of Computer Sciences Corp., an international consulting company headquartered in Falls Church, Va., noted in a July report.
Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would improve treatment and survival rates for some women.
Amgen announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer.
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).
› Verified 8 days ago
Paula Castor, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 245 Torrey Pine Ct, West Chester, PA 19380 Phone: 610-363-9398 | |
Kathleen Ann Messick, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1249 W Chester Pike, West Chester, PA 19382 Phone: 610-692-9244 Fax: 610-692-0621 | |
Mrs. Stacy Kiraly-duran, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 907 Paoli Pike, West Chester, PA 19380 Phone: 610-431-6270 | |
Megan Finan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1375 E Boot Rd, West Chester, PA 19380 Phone: 610-241-1064 | |
Naimesh Mukundbhai Patel, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1249 W Chester Pike, West Chester, PA 19382 Phone: 610-692-9244 Fax: 610-692-0621 | |
Jenny Vangelatos I, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 829 Kenmara Dr, West Chester, PA 19380 Phone: 610-918-8256 Fax: 610-918-8256 | |
Dr. Anthony Ernest Angelucci, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 760 Miles Rd, West Chester, PA 19380 Phone: 610-429-3477 Fax: 610-696-7399 |